Blue rose reveals true RNAi colours
Wednesday, 30 March, 2005
The CSIRO has revealed that part of the technology used to develop the blue rose -- unveiled last year by Japanese giant Suntory and its subsidiary, Melbourne company Florigene -- was an RNAi technique developed by CSIRO for gene replacement in plants.
In its first commercial application in plants, the CSIRO-developed RNAi technology was used to inactivate the gene encoding the enzyme dihydroflavonol reductase (DFR) in roses. The enzyme directs the synthesis of red pigments in the flower.
An RNAi molecule which hybridises with the rose DFR gene was used to inhibit the gene's expression. Scientists then inserted Florigene's patented iris DFR gene -- which makes a lot of blue pigment - plus the delphinidin gene from pansy, a gene missing in roses, to produce a blue rose.
The blue rose has yet to gain regulatory approval before it can be commercially grown and marketed.
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
Placebos appear to reduce PMS symptoms
Women affected by premenstrual syndrome (PMS) appear to experience less intense and debilitating...
Medicinal cannabis linked to long-term health benefits
As scientists find a way to improve the effectiveness of CBD, a separate study shows that...
